EJHaem · 2026
Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post-Marketing Surveillance Sub-Analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ikezoe Takayuki, Kawaguchi Tatsuya, Hayashi Hideo, Shimono Akihiko, Nishimura Jun-Ichi
Аннотация
BACKGROUND: Thrombotic events (TEs) account for approximately 40%-67% of deaths in untreated paroxysmal nocturnal haemoglobinuria (PNH). C5 inhibitor treatment (e.g., eculizumab and ravulizumab) greatly reduces the incidence of TEs in patients with PNH, but data on the characteristics of PNH patients experiencing TEs are limited.
METHODS: This post-marketing surveillance sub-analysis evaluated the incidence of TEs in patients with PNH in Japan.
RESULTS: During eculizumab treatment, 54 TEs occurred in 44/794 patients (5.5%), an incidence of 1.50/100 patient-years. The most frequent TEs were deep vein thrombosis and cerebral infarction (eight events [14.8%]). A history of TE before eculizumab treatment was associated with TE during eculizumab treatment (p = 0.014), and greater cumulative incidences of TEs and multiple TEs during treatment (both p = 0.003) versus no history of TE. TEs were more frequent during the antithrombotic agent off-period (71.8%, 28/39) than during the on-period (28.2%, 11/39). TEs during eculizumab treatment were observed in patients with high lactate dehydrogenase (LDH) levels, infection events and longer administration intervals. Within the week before TE onset, LDH levels > 1.5 × the upper limit of normal were observed in 8/13 patients with TEs (61.5%), suggesting that intravascular haemolysis is not adequately suppressed in these patients.
CONCLUSION: Eculizumab helps prevent TEs in PNH. TE events appear to be associated with higher LDH levels, infections and long dosing intervals. Concurrent antithrombotic agent use to prevent TEs in PNH is likely clinically useful, especially in patients with a history of TE.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
METHODS: This post-marketing surveillance sub-analysis evaluated the incidence of TEs in patients with PNH in Japan.
RESULTS: During eculizumab treatment, 54 TEs occurred in 44/794 patients (5.5%), an incidence of 1.50/100 patient-years. The most frequent TEs were deep vein thrombosis and cerebral infarction (eight events [14.8%]). A history of TE before eculizumab treatment was associated with TE during eculizumab treatment (p = 0.014), and greater cumulative incidences of TEs and multiple TEs during treatment (both p = 0.003) versus no history of TE. TEs were more frequent during the antithrombotic agent off-period (71.8%, 28/39) than during the on-period (28.2%, 11/39). TEs during eculizumab treatment were observed in patients with high lactate dehydrogenase (LDH) levels, infection events and longer administration intervals. Within the week before TE onset, LDH levels > 1.5 × the upper limit of normal were observed in 8/13 patients with TEs (61.5%), suggesting that intravascular haemolysis is not adequately suppressed in these patients.
CONCLUSION: Eculizumab helps prevent TEs in PNH. TE events appear to be associated with higher LDH levels, infections and long dosing intervals. Concurrent antithrombotic agent use to prevent TEs in PNH is likely clinically useful, especially in patients with a history of TE.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.